PF-05175157 NEW
| Price | $61 | $97 | $193 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: PF-05175157 | CAS No.: 1301214-47-0 |
| Purity: 99.92% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | PF-05175157 |
| Description | PF 05175157 is an inhibitor of acetyl-CoA carboxylase 1 (ACC1) and ACC2 (IC50s = 27, 33, 23.5, and 50.4 nM for human ACC1, human ACC2, rat ACC1, and rat ACC2, respectively |
| Animal Research | Pharmacokinetics was analyzed after a single oral dose of the compounds (in a 0.5% methyl cellulose suspension) administered to fasted male mice. A dose of 15 mg/kg for PF-05175157 or 100 mg/kg in the case of PF-05206574 and PF-06256254 was analyzed. Antiviral activity in vivo was determined using eight-week-old Swiss albino CD-1 female mice. Animals were treated with PF-05175157 (20 mg/kg) suspended in 1% carboxymethylcellulose by oral gavage twice a day from 1 d before infection with WNV (1 × 10^4 PFU/mouse intraperitoneally) and up to 7 days post-infection. Control mice were treated in parallel with drug vehicle (carboxymethylcellulose). For experiments evaluating the effect of genetic deletion of ACC2 gene on WNV infection, a breeding colony of C57BL/6 ACC2-/- mice was established from two heterozygous Acabtm1Dejs females . Age- and sex-matched eight-week-old ACC2-/- and control wild type (WT) mice were challenged with WNV (1 × 10^4 PFU/animal.). Animals were monitored daily and received water and food ad libitum. |
| In vivo | PF-05175157 induced a reduction of the viral load in serum and kidney in WNV-infected mice, unveiling its therapeutic potential for the treatment of chronic kidney disease associated with persistent WNV infection. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : 10 mg/mL (24.66 mM), Suspension. DMSO : 140 mg/mL (345.26 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.47 mM), Sonication is recommended. |
| Keywords | PF-05175157 | PF05175157 | PF 05175157 | Inhibitor | inhibit | AcetylCoACarboxylase | Acetyl-CoA Carboxylase | AcetylCoA Carboxylase | ACC, Acetyl Coenzyme A Carboxylase | ACC |
| Inhibitors Related | Alisol A | CMS-121 | Cyhalofop-butyl | Acetyl-CoA Carboxylase-IN-1 | Firsocostat | PF-05221304 | Clethodim | Clodinafop-propargyl | VY-3-135 | Quizalofop-ethyl | TOFA | Tralkoxydim |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Obesity Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-05 | ||
| $1980.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
|
VIP3Y
|
Qingdao RENAS Polymer Material Co., Ltd.
|
2026-07-01 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY